# Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma

> **NCT01555281** · PHASE1,PHASE2 · TERMINATED · sponsor: **Swiss Cancer Institute** · enrollment: 33 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Nelfinavir
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01555281
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-02-23
- **Primary completion:** 2022-06-08
- **Final completion:** 2022-06-08
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** In connection with the restructuring of SAKK, older ongoing studies were analyzed to determine whether a continuation of the trial would still add value to the data analysis, or whether they do not and could therefore be prematurely terminated.
- **Last updated:** 2022-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01555281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01555281, "Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT01555281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*